Introduction {#s1}
============

Extracellular ATP is a danger associated molecular pattern (DAMP), which can act through the P2 receptor family including ionotropic P2X ion channel receptors and the G protein-coupled P2Y receptor family ([@B1]; [@B58]; [@B347]; [@B257]; [@B62]). The P2X receptor family is formed by seven members able to assemble into homo- and hetero-trimers at the cell membrane ([@B257]; [@B61]). P2X family members are distinguished by their relative affinities to ATP, within the nanomolar range for P2X1 and P2X3, the low micromolar range for P2X2, P2X4, and P2X5 and the hundreds of micromolar range for P2X7 and also their rate of channel desensitization, milliseconds for P2X1 and P2X3, seconds for P2X2, P2X4, and P2X5 and no observable desensitization for P2X7, ([@B203]; [@B256]; [@B257]; [@B61]; [@B183]; [@B368]; [@B75]).

P2X7 is characterized by its biphasic response to ATP stimulation. Upon activation with ATP for a relatively short period (2s or less), P2X7 opens a nonselective cation channel facilitating Na^+^ and Ca^2+^ influx and K^+^ efflux while prolonged ATP stimulation (4s or above) leads to the formation of a macropore permeable to molecules of \<900 Da. However, recent reports have shown that ATP activated P2X7 receptors can open a NMDG^+^-permeable macropore within milliseconds and without progressive dilatation ([@B166]; [@B280]). Formation of this large molecular weight-permeable pore has been associated with the release of ATP in the microenvironment ([@B271]; [@B6]). Extracellular ATP helps to sustain macropore opening and is likely to drive several physiological and pathological mechanisms including chronic pain ([@B328]), proliferation and activation of microglia ([@B49]; [@B246]) and the death of enteric neurons during colitis ([@B159]). In healthy tissues, P2X7 is expressed mainly in the central nervous system (CNS), peripheral nervous system (PNS), and in immune cells, which supports its emergence as a target for chronic pain and chronic inflammatory diseases ([@B85]). P2X7 is also overexpressed in a number of cancer types, potentially driving tumor development and survival ([@B2]; [@B5]; [@B7]; [@B35]; [@B20]; [@B36]; [@B137]).

As a consequence of its ion channel activity, P2X7 is involved in driving several functions known to be important during tumor initiation and progression ([@B97]). Yet, analysis of sequencing repositories from large tumor panels, including deep sequencing initiatives, does not highlight the preferential selection of mutation or copy number variation in the P2RX7 gene by tumor cells ([@B209]). This suggests that other receptor control mechanisms might modulate the critical role P2X7 plays during cancer progression. Extracellular ATP is present at low levels in healthy tissues but increases dramatically in response to tissue damage, inflammation, hypoxia, ischaemia and in the tumor microenvironment (TME). This increase in extracellular ATP has been attributed to cell death, cell stress, vesicular release, activation of pannexin and connexin, and to ATP-binding cassette (ABC) transporters ([@B272]; [@B109]; [@B123]). In the TME, extracellular ATP is hydrolyzed into AMP by the ectonucleotidase CD39, AMP is then hydrolyzed into adenosine by the CD73 ectonucleotidase ([@B15]). While extracellular ATP acts as a DAMP to trigger proinflammatory immune responses, adenosine was found to be a potent immunosuppressor ([@B97]). In this context, P2X7 collaboration with purinergic related proteins such as CD39 and Pannexin 1, was found to play an important role in the regulation of the antitumor immune response ([@B84]).

The high extracellular ATP concentration found in the TME is sufficient to open the P2X7 macropore that could in turn lead to membrane depolarization and ultimately to cell death. To support tumor progression, cancer cells need to inhibit P2X7 macropore activity while retaining other receptor signaling functions. Several studies have described molecular mechanisms that lead to loss or attenuation of macropore function (See [**Table 1**](#T1){ref-type="table"}). These include the report of a misfolded form of P2X7 termed nonfunctional P2X7 (nfP2X7) that is characterized by the exposure of an extracellular epitope named E200 ([@B134]; [@B35]; [@B137]). In this review we seek to describe how the interplay between P2X7 functions drive tumor progression and immune escape. We first present the topological features, functions and processes activated downstream of the P2X7 receptor before discussing how the interplay between these features may explain the paradoxical role of P2X7 in the tumor and the immune compartment. We then discuss the expression and role of P2X7 across multiple cancer types before reviewing the therapeutic approaches taken to target P2X7 to date.

###### 

Channel modifications leading to the loss or gain of P2X7 macropore function.

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Designation                                                   Type of modification                             Outcome                                                                                                               Reference
  ------------------------------------------------------------- ------------------------------------------------ --------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------
  **Modification leading to Loss of P2X7 Macropore function**                                                                                                                                                                          

  V76A                                                          SNP                                              Partial loss of macropore function                                                                                    ([@B332]; [@B260])

  R117W                                                         SNP                                              Partial loss of channel and macropore function                                                                        ([@B295]; [@B363]; [@B187])

  G150R                                                         SNP                                              Loss of macropore function                                                                                            ([@B332])

  E186K                                                         SNP                                              Loss of channel and macropore function                                                                                ([@B295]; [@B363]; [@B187])

  N187D                                                         SNP                                              Possible loss of function                                                                                             ([@B73])

  L191P                                                         SNP                                              Partial loss of channel and macropore function                                                                        ([@B295]; [@B363]; [@B187])

  R276H                                                         SNP                                              Loss of macropore function                                                                                            ([@B332])

  R307Q                                                         SNP                                              Loss of macropore function                                                                                            ([@B150]; [@B126]; [@B188]; [@B156])

  A348T                                                         SNP                                              Mild increase of channel function in human P2X7 and mild decrease in channel function in rat P2X7                     ([@B63]; [@B57])

  T357S                                                         SNP                                              Partial loss of channel and macropore function                                                                        ([@B63]; [@B312])

  Q460R                                                         SNP                                              Partial loss of channel and macropore function                                                                        ([@B63]; [@B332])

  E496A                                                         SNP                                              Loss of channel and macropore function                                                                                ([@B149]; [@B52]; [@B63]; [@B295]; [@B333]; [@B135]; [@B357]; [@B187])

  I568N                                                         SNP                                              Loss of channel and pore function due to impaired P2X7 trafficking to the plasma membrane                             ([@B362])

  P2X7 variant B                                                Splice variant                                   Loss of macropore function (P2X7 variant A and B coexpression leads to gain of macropore function)                    ([@B68]; [@B6])

  P2X7 variant C                                                Splice variant                                   Assumed to have lost macropore function                                                                               ([@B68]; [@B43])

  P2X7 variant D                                                Splice variant                                   Assumed to have lost macropore function                                                                               ([@B68]; [@B43])

  P2X7 variant E                                                Splice variant                                   Assumed to have lost macropore function                                                                               ([@B68]; [@B43])

  P2X7 variant F                                                Splice variant                                   Assumed to have lost macropore function                                                                               ([@B68]; [@B43])

  P2X7 variant G                                                Splice variants                                  Loss of macropore function                                                                                            ([@B68]; [@B43])

  P2X7 variant H                                                Splice variants                                  Loss of macropore function                                                                                            ([@B68])

  P2X7 variant J                                                Splice variant                                   Loss of macropore function\                                                                                           ([@B114])
                                                                                                                 (P2X7 variant J act as a dominant negative when coexpressed with P2X7 variant A leading to loss macropore function)   

  N187A                                                         Impaired N-glycosylation                         Loss of macropore function                                                                                            ([@B212])

  R578Q                                                         Impaired N-glycosylation                         Loss of macropore function                                                                                            ([@B360])

  R277 or Y298                                                  Proteolytic cleavage                             Loss of macropore function following MMP-2 cleavage of P2X7 extracellular domain                                      ([@B375])

  C-terminal tail                                               Binding partner                                  NMMHC-IIA                                                                                                             ([@B161]; [@B151])

  TM domains                                                    Cholesterol binding                              Loss of macropore function                                                                                            ([@B294]; [@B194])

  C362S and C363S                                               Prevent cholesterol inhibition rescue            Loss of macropore function                                                                                            ([@B194])

  **Modification leading to Gain of P2X7 Macropore function**                                                                                                                                                                          

  H155Y                                                         SNP                                              Gain of macropore function                                                                                            ([@B63]; [@B332]; [@B260]; [@B187])

  A166G                                                         SNP                                              Gain of macropore function                                                                                            ([@B187])

  H270R                                                         SNP                                              Gain of macropore function                                                                                            ([@B332])

  R125                                                          ADP-ribosylation of mouse P2X7                   Gating of mouse P2X7 macropore                                                                                        ([@B13])

  R206K, R276K, R277K (mouse)                                   Mutation                                         Gain of macropore function in mouse P2X7                                                                              ([@B13])

  TM domain                                                     phosphatidylglycerol and sphingomyelin binding   Gain of macropore function                                                                                            ([@B194])
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Topology of the P2X7 Receptor {#s1_1}
-----------------------------

The human *P2RX7* gene is located on chromosome 12 and encodes 13 exons that translate into a 595 amino acid protein. The location of *P2RX7* (12q24.31) is adjacent to the *P2RX4* gene, which is only 20Mbp downstream in the same reading direction ([@B59]). Both genes are believed to be derived from successive gene duplications ([@B106]; [@B173]). Indeed, a recent report suggests that P2X7 was probably formed in lower vertebrates through the fusion of a P2X4-like gene with a Zn-coordinating cysteine-based domain (ZCD) coding exon ([@B299]). While heteromerisation of P2X7 and P2X4 *in vivo* is still controversial, both genes are found to be widely coexpressed ([@B161]; [@B189]) and colocalize to act in concert in the regulation of the same physio-pathological functions ([@B202]). Thirteen P2X7 splice variants have been identified to date ([@B43]). While the resolution of the structure of human P2X7 has not yet been achieved, due to its propensity to aggregate, the partial structure of human P2X3 ([@B229]), zebra fish P2X4 ([@B198]; [@B167]; [@B195]), chicken P2X7 ([@B196]), panda P2X7 ([@B193]; [@B194]), and more recently the full-length rat P2X7 ([@B232]) have been resolved. These have begun to reveal the molecular mechanism of ATP channel gating and the topology of the P2X7 trimer at the cell membrane. The P2X7 receptor is divided into five main structural domains ([**Figure 1**](#f1){ref-type="fig"}).

![Topology of the P2X7 receptor. **(A)** Five main structural domains are present within each P2X7 monomer **(B)** Positioning of P2X7 monomer in the trimer. Rendering were generated from the rat P2X7 structure (PDB file 6U9W) ([@B232]) and positioned together with ATP, palmitoyl groups and GDP (GTP) molecules in relation to the plasma membrane (PM). Rendering were performed using PyMOL (<https://pymol.org/>).](fphar-11-00793-g001){#f1}

### N-Terminal Cytoplasmic Tail {#s1_1_1}

A short N-terminal cytoplasmic tail of 25 amino acids (aa), which is anchored in the membrane *via* the palmitoylation of a cysteine residue at position 4 to form a cytoplasmic cap involved in the sensitisation of the channel to its agonist through key residues such as T15 and Q17 ([@B368]; [@B232]; [@B218]).

### First Transmembrane Domain (TM1) and Extracellular Domain {#s1_1_2}

The N-terminal cytoplasmic tail is followed by a first transmembrane domain named TM1 (aa 26 to 46) and a large extracellular domain of 282 aa (aa 47 to 329), which contains an inter-subunit ATP binding pocket ([@B165]; [@B167]; [@B194]; [@B232]). The extracellular domain also includes 5 disulfide bonds between cysteine residues 119--168, 129--152, 135--162, 216--226, and 260--269, which play a critical role in maintaining the conformation of the extracellular domain. These disulfide bridges are homologous across the other members of the P2X receptors which suggest that they form highly conserved protein folds ([@B165]). Several post-translational modifications have been identified in the P2X7 extracellular domain which can regulate receptor functions; these include ADP-ribosylation of R125 on murine P2X7 that is involved in the gating of the murine P2X7 receptor ([@B310]) and N-linked glycosylation of 5 asparagine residues (D187, D202, D213, D241, and D284) with D187 N-linked glycosylation playing a key role in the regulation of P2X7 signaling through the MAP kinase pathway ([@B212]).

### Second Transmembrane Domain (TM2) {#s1_1_3}

The extracellular region is followed by a second transmembrane domain named TM2 (aa 330 to 349), which contains several key pore-lining residues. These include S342, which sits at the narrowest part of the channel to regulate its gating ([@B280]; [@B232]). Phosphorylation of the adjacent Y343 also regulates channel gating which further emphasizes the importance of those two residues during channel gating ([@B201]; [@B218]).

### C-terminal Cytoplasmic Tail {#s1_1_4}

The second transmembrane domain is flanked by a long C-terminal cytoplasmic tail of 245 aa (aa 350 to 595), which acts as a ballast and is involved in the modulation of macropore opening ([@B336]; [@B68]; [@B77]; [@B232]). The beginning of the C-terminal tail contains a cysteine rich region that is palmitoylated on at least five residues (C362, C363, C374, C377, and S360) and plays an important role in trafficking of the receptor to the cell membrane and in preventing receptor desensitization ([@B140]; [@B232]). These multiple palmitoylated residues act as a hinge allowing each C-terminal tail to create two zinc binding sites and a guanosine diphosphate or triphosphate (GDP/GTP) binding site. From a functional perspective, the C-terminal tail has been shown to be required for the opening of the macropore ([@B336]; [@B6]). Recent reports have also shown that pore opening requires movement of the TM2 helix which is directly linked to the globular ballast folded underneath ([@B280]; [@B232]). This suggests that a significant movement of the ballast is needed to allow for the macropore to form (See [**Figures 1**](#f1){ref-type="fig"} and [**2**](#f2){ref-type="fig"}). Given the presence of GDP/GTP binding sites in the P2X7 C-terminal tail, it is tempting to hypothesize that such a structural rearrangement may involve an exchange between GDP and GTP. This type of mechanism has already been extensively characterized for GTPase enzymes, which promote the hydrolysis of GTP to GDP to trigger protein interaction and signaling cascades ([@B54]). This switch could either be mediated by P2X7 itself or through accessory proteins such as GTPase-activating proteins (GAPs) and guanine nucleotide exchange factors (GEFs). However, further work is needed to confirm this hypothesis.

![Activation of P2X7 receptor. Structures show the top **(A)** and side view **(B)** of the P2X7 trimer in the Apo-closed state (PDB file: 6U9V) and ATP bound open state (PDB file: 6U9W). Each monomer is represented in a different color (blue, red or yellow). ATP binding to the trimer leads to a rotation of each monomer around its respective turret leading to the opening of a side fenestration and an ion channel through the plasma membrane (PM). Renderings were generated from the rat P2X7 structure ([@B232]) using PyMOL (<https://pymol.org/>).](fphar-11-00793-g002){#f2}

P2X7 Possesses Ion Channel Functionality {#s2}
========================================

P2X7 is distinguished from other P2X family members by its relative insensitivity to its natural agonist ATP (EC~50~ above 80 −100 µM) ([@B336]). ATP binding to the inter-subunit pocket leads to a rotation of each subunit around its turret and a widening of the lower body of the P2X7 trimer. This conformational rearrangement is associated with the opening of a lateral fenestration in the lower body of the trimer that in turn allows influx of Ca^2+^ and Na^+^ ions into and the efflux of K^+^ ions from the cell ([**Figures 2A, B**](#f2){ref-type="fig"}) ([@B193]; [@B232]). Several well characterized small molecule inhibitors have been reported to inhibit this mechanism through binding to an allosteric pocket located in between the turret of each subunit, thereby preventing the closure of the turret necessary for the opening of the channel ([**Figures 2A, B**](#f1){ref-type="fig"}) ([@B193]). Observations made using rat P2X7 suggest that the C-terminal cytoplasmic tail does not significantly regulate receptor current facilitation, desensitization, affinity for ATP or its receptor ion selectivity ([@B232]).

###### 

Studies confirming the presence of P2X7.

  Cancer type                                                 Studies confirming the presence of P2X7
  ----------------------------------------------------------- -----------------------------------------------------------------------------------------------------------------------------------------------------------
  Prostate                                                    ([@B319]; [@B321]; [@B228]; [@B5]; [@B34]; [@B288]; [@B6]; [@B35]; [@B130]; [@B284]; [@B326]; [@B36]; [@B137])
  Lung                                                        ([@B34]; [@B340]; [@B185]; [@B35]; [@B341]; [@B308]; [@B137])
  Kidney                                                      ([@B221]; [@B137])
  Colorectal                                                  ([@B79]; [@B34]; [@B215]; [@B206]; [@B46]; [@B35]; [@B36]; [@B283]; [@B137]; [@B381])
  Gastric                                                     ([@B34]; [@B35]; [@B64])
  Breast                                                      ([@B320]; [@B34]; [@B215]; [@B338]; [@B184]; [@B175]; [@B185]; [@B35]; [@B66]; [@B383]; [@B343]; [@B105]; [@B367]; [@B36]; [@B265]; [@B137]; [@B266])
  Cutaneous squamous-cell and basal-cell carcinomas           ([@B143]; [@B317]; [@B36]; [@B370]; [@B136])
  Melanoma                                                    ([@B318]; [@B358]; [@B311]; [@B290]; [@B35]; [@B296]; [@B137])
  Leukemia and lymphoma                                       ([@B273]; [@B148]; [@B2]; [@B361]; [@B33]; [@B378]; [@B379]; [@B373]; [@B34]; [@B76]; [@B72]; [@B73]; [@B355]; [@B35]; [@B69]; [@B210]; [@B301]; [@B302])
  Neuroblastoma                                               ([@B190]; [@B309]; [@B287]; [@B335]; [@B162]; [@B47]; [@B20]; [@B139]; [@B364]; [@B346]; [@B137])
  Glioma                                                      ([@B356]; [@B342]; [@B300]; [@B339]; [@B128]; [@B113]; [@B35]; [@B129]; [@B234]; [@B186]; [@B44]; [@B191])
  Ovarian                                                     ([@B35]; [@B348]; [@B137])
  Cervical and endometrial                                    ([@B114]; [@B115]; [@B213]; [@B214]; [@B34]; [@B35])
  Bladder                                                     ([@B34]; [@B35]; [@B174]; [@B137])
  Papillary Thyroid                                           ([@B298]; [@B325]; [@B34]; [@B215]; [@B83]; [@B153]; [@B35]; [@B208])
  Pancreatic                                                  ([@B205]; [@B244]; [@B35]; [@B132]; [@B133]; [@B71]; [@B137])
  Bone (osteosarcoma, Ewing sarcoma, chondromyxoid fibroma)   ([@B125]; [@B18]; [@B34]; [@B219]; [@B8]; [@B35]; [@B138]; [@B380])
  Head and neck                                               ([@B34]; [@B35]; [@B29])
  Testicular                                                  ([@B34]; [@B35])
  Esophageal                                                  ([@B34]; [@B35]; [@B303])
  Trophoblastic                                               ([@B34]; [@B35])
  Mesothelioma                                                ([@B34]; [@B35]; [@B21])

Structural analysis of P2X family members together with experimental characterization and mathematical modeling have provided insights into the transition states of the P2X7 receptor following ATP binding. While occupation of all three ATP binding sites on the trimer leads to a symmetric conformational rearrangement and to channel gating, the binding of a single ATP molecule leads to an asymmetric rearrangement of the trimer leaving the fenestration closed and decreasing the affinity of the second and third ATP binding sites. Upon binding of a second ATP molecule, a low conductance is observed with a further decrease in the affinity of the third ATP binding site ([@B368]). These observations explain why P2X7 is relatively insensitive to ATP compared to other P2X family members. The functional implication is that P2X7 ion channel activation is only achieved when the level of ATP is significantly elevated in the extracellular compartment. Such conditions can be found in the TME, during inflammatory responses and in chronic inflammatory diseases. In these settings, P2X7 mediated calcium signaling was shown to trigger intracellular signaling and changes in gene expression that are critical for cancer cell survival and proliferation ([@B101]; [@B96]; [@B97]). Indeed, overexpression of full length P2X7 was shown to promote tumor growth ([@B184]; [@B7]), while P2X7 blockade was shown to inhibit neoplastic growth in several experimental models ([@B7]; [@B9]; [@B20]; [@B21]; [@B133]; [@B86]; [@B380]).

P2X7 Activation Can Open a Transmembrane Macropore {#s3}
==================================================

Evidence for ATP-induced dye uptake was first identified in the 1970s and 80s ([@B297]; [@B74]; [@B329]) but it was only a decade later that P2X7, previously known as P2Z, was shown to play a key role in the formation of a transmembrane dye-permeable macropore ([@B336]; [@B350]). The formation of a transmembrane pore is not believed to be limited exclusively to P2X7. Other ion channels including P2X2, P2X4, TRPV1 and ASICs have also been shown to increase conductance and allow molecules of \<900 Da into the cell ([@B200]; [@B216]). However, while P2X2, P2X4, TRPV1, and ASICs undergo a "channel to pore dilatation" upon prolonged activation, P2X7 pore opening is almost instantaneous (within milliseconds) ([@B216]; [@B280]).

While demonstration of the P2X7 macropore has been described extensively *in vitro* ([@B98]), opening of the macropore *in vivo* remains to be demonstrated. Opening of the macropore allows the flow of ions across the membrane leading to rapid membrane depolarization and ultimately to cell death. *In vitro* assessment of macropore opening is typically performed by measuring the increase in fluorescence associated with the influx of ethidium^+^ (314 Da), YO-PRO-1^2+^ (375 Da), Lucifer yellow (444 Da), DAPI (277 Da) or the current associated with N-methyl-D-glucamine^+^ (NMDG^+^, 195 Da) influx ([@B100]). Given the significant risk that an open macropore may have on cell viability, the low sensitivity of P2X7 for ATP provides a first mechanism of protection for cells. Furthermore, P2X7 macropore opening has been shown to be reversible upon the removal of ATP within 10 to 15 min from initiation of stimulation in a mouse macrophage cell line, however reversibility may be cell type specific ([@B92]; [@B98]). This reversible closure of the macropore can potentially provide a second mechanism to protect cells from P2X7-mediated cell death. Although the advantages of gated opening of the P2X7 pore are not well understood, such transient mechanisms could allow small molecules, such as peptides and micro-RNA, to enter or leave the cell ([@B92]) as observed for connexins and pannexins at cell to cell junctions ([@B111]). The demonstration that P2X7 is permeable to the large natural cation spermidine, a polyamine molecule involved in cell survival, supports this hypothesis ([@B166]). Since opening of a high conductance transmembrane conduit has inevitable dire consequences on cell survival, it is likely that under more physiological conditions, localized opening of the P2X7 macropore occurs that will perturb cytoplasmic ion homeostasis at discrete sites only ([@B122]).

The mechanism(s) leading to macropore opening have been the subject of much controversy. Several hypotheses have been proposed to support P2X7 dilatation in response to sustained agonist stimulation and the involvement of associated proteins such as pannexin-1 (Reviewed in ([@B96]; [@B98])). However, recent analysis of human and rat P2X7 electrophysiological activity in response to agonist shows that the macropore function is intrinsic to P2X7 and does not involve progressive pore dilatation ([@B166]; [@B280]). Extracellular ATP is present at concentrations in the low nanomolar range in healthy tissue but can increase dramatically upon tissue damage, inflammation or during tumor development to the tens to hundreds of micromolar range and reach the high activation threshold of 0.3 to 0.5mM for P2X7 ([@B101]; [@B249]; [@B98]). We demonstrated that antibodies raised against the E200 epitope of P2X7 bind specifically to cancer cell lines that are devoid of macropore function but that retain P2X7 ion channel function ([@B33]; [@B137]). In these cell lines, overexpressed wild type P2X7 rescues macropore function but is not detected by antibodies that target E200 supporting the specific exposure of E200 epitope by nfP2X7 ([@B137]). E200 specific antibodies were used to show that nfP2X7 is present intracellularly and can be released to the plasma membrane upon stimulation with KM11060, a small molecule corrector that increases the secretion rate of misfolded proteins to the membrane as shown previously for the Cystic Fibrosis Transmembrane Receptor (CFTR) mutants ([@B292]). nfP2X7 was also shown to be necessary for cell survival ([@B137]). Hence, these data suggest that to sustain growth without compromising survival, cancer cells expressing high levels of P2X7 have developed a mechanism to inhibit macropore function while retaining ion channel functionality ([@B137]).

Although mutations of *P2X7,* such as E496A, have been shown to abrogate the macropore ([@B149]; [@B131]), we and others have demonstrated that P2X7 is expressed at the cell membrane in the absence of mutations such as E496A. This suggests that additional mechanisms are involved in protecting cancer cells ([@B137]). Indeed, several other mechanisms have been shown to modulate P2X7 macropore activity. These include splice variants ([@B43]), N-glycosylation ([@B212]), ADP-ribosylation ([@B13]), proteolytic cleavage ([@B375]), and interactions with binding partners or other P2X family members ([@B161]; [@B151]). They also include interactions with cholesterol in the membrane ([@B294]; [@B194]), that may attenuate or abrogate P2X7 macropore formation (summarized in [**Table 1**](#T1){ref-type="table"}). One or more of these mechanisms has the potential to protect cells that possess P2X7 receptors in a high ATP microenvironment over a sustained time period.

P2X7 as a Scavenger Driving Phagocytosis {#s4}
========================================

Further to its ability to open an ion channel and macropore, P2X7 has also been shown to act as a scavenger receptor promoting phagocytosis of nonopsonised targets such as apoptotic cells, latex beads and live or dead bacteria (Staphylococcus *aureus* and Escherichia *coli*) under serum free conditions ([@B152]; [@B154]; [@B155]). Binding of P2X7 to the nonmuscle myosin heavy chain (NMMHC-IIA) was shown to be required for the engulfment of particles ([@B152]; [@B154]). This function is inversely correlated with P2X7 macropore opening, which requires NMMHC-IIA dissociation from P2X7 upon ATP stimulation ([@B151]; [@B152]; [@B154]). P2X7 mediated phagocytosis was first demonstrated in monocytes and macrophages before being extended to microglia cells in the CNS where it plays a critical role in the clearance of nonopsonised particles and debris involved in neuro-inflammation ([@B363]; [@B146]; [@B182]). The ability of the P2X7-NMMHC-IIA complex to act as a scavenger suggests another P2X7-mediated role for macrophages infiltrated in the TME where P2X7 would recognize and promote the phagocytosis of apoptotic cells and potentially support the presentation of associated antigen to immune effector cells. Indeed, during inflammation and in the TME, the extracellular ATP concentration is significantly higher than in healthy tissues ([@B97]). Under these conditions, P2X7 (as well as P2X4) stimulation potentiates phagocytosis by inflammatory macrophages ([@B385]).

Downstream Effect of P2X7 Activation {#s5}
====================================

Several signaling pathways are activated downstream of P2X7 including hypoxia and proinflammatory pathways *via* hypoxia-inducible factor 1a (HIF-1α), nitric oxide synthase (NOS2), cyclooxygenase 2 (COX2) and acute phase protein pentraxin-3 (PTX3) ([@B338]). Downstream effects of P2X7 activation also include survival and proliferation pathways such as the NF-κB ([@B338]; [@B220]), NFATc1 ([@B5]), Phosphoinositide 3-kinases (PI3Ks) ([@B46]; [@B20]), mitogen-activated kinases (MAPK) ([@B56]; [@B22]), phospholipase A2, C and D ([@B176]; [@B78]; [@B23]) acid sphingomyelinase ([@B50]) and myc oncogene ([@B20]).

The regulation of downstream signaling pathways by P2X7 is defined at three levels. First, the concentration and duration of agonist exposure. While acute exposure to relatively high amounts of ATP has been shown to activate PI3K/AKT and AMPK-PRAS-40-mTOR signaling pathways to trigger tumor cell death ([@B46]), lower and chronic activation has been shown to activate the NOD-like receptor containing a pyrin (NLRP3) inflammasome pathway. Second, regulation may involve the interaction of P2X7 with other membrane proteins, such as other P2X family members or Pannexin 1. Third, interaction with scaffolding proteins associated with the cytoskeleton such as NMMHC-IIA ([@B151]). Indeed, the P2X7 receptor signaling complex has been shown to regulate the macropore and interact with the actin cytoskeleton machinery ([@B201]). These three levels of regulation are involved in several mechanisms that are key to cancer progression.

Cell Death {#s5_1}
----------

The early discovery of the P2X7 macropore drove interest in P2X7 as a receptor capable of mediating cell death through disruption of intracellular homeostasis and cytolysis leading to necrosis ([@B377]; [@B336]). However, many reports have highlighted cell death mechanisms associated with P2X7 activation that are typical of an apoptotic pathway. These include membrane depolarization, redistribution of phosphatidylserine (PS) to the outer membrane, caspase 3, 8 and 9 activation and membrane blebbing ([@B377]; [@B117]; [@B177]; [@B227]). Interestingly, the recent resolution of the rat P2X7 structure has highlighted the presence of a putative phospholipid in a perpendicular position to the transmembrane helices in the middle of the plasma membrane that led McCarthy and colleagues to suggest that P2X7 might possess an intrinsic flippase-like function driving PS redistribution to the outer membrane ([@B232]).

Proliferation {#s5_2}
-------------

The notion that the P2X7 receptor, together with mediating cytotoxic activity, also exerts a proliferative drive dates back to 1999, when in a pivotal paper from Baricordi and colleagues, it was demonstrated that transfection with the receptor conferred a proliferative advantage to leukaemic cell lines growing in the absence of serum ([@B38]). In the following years, the trophic activity of P2X7 was associated with an increase in mitochondrial function leading to an augmented production of intracellular ATP ([@B4]) and, in general, to increased levels of calcium inside cellular stores ([@B5]).

P2X7 calcium channel activity plays a central role in driving proliferation and is shared by the human splice variant P2X7B that retains ion channel activity while losing the ability to form a macropore ([@B6]). When transfected in the osteosarcoma cell line Te85, P2X7B causes an increase in proliferation that is even greater than that attributable to transfection of P2X7A ([@B138]). Several calcium-related intracellular pathways involved in cell proliferation were shown to be activated by the P2X7 receptor. These include the JNK/MAPK, PI3K/AKT/myc and HIF1α-VEGF pathways ([@B8]; [@B10]; [@B95]; [@B91]; [@B258]). Among these, the nuclear factor of activated T cells (NFAT) pathway is one of the best characterized. NFAT is a calcium-calcineurin activated nuclear factor involved in the proliferation of several cell types including T lymphocytes where P2X7-dependent activation of NFAT was shown to facilitate clonal expansion and IL-2 secretion thus positively influencing lymphocytic growth ([@B376]). NFATc1 mediated pathway was also responsible for increased proliferation of HEK-293 ([@B5]; [@B6]) and Te85 cells transfected with both P2X7A and B isoforms ([@B138]) and was found to be upregulated in xenografts overexpressing the receptor ([@B7]).

Association between P2X7, proliferation and survival has been demonstrated in several primary cell types including osteoblasts ([@B144]; [@B14]; [@B371]), microglia ([@B246]), and CD8^+^ memory T cells ([@B53]) where it supports physiological functions such as inflammatory responses and osteogenesis. However, increased P2X7 activity was also linked with increased proliferation and survival in many cancer cell types including pancreatic cancer ([@B133]), leukemia ([@B301]) and glioma ([@B186]). Indeed, reports showing enhanced P2X7 expression in tumor tissues compared with normal tissue across many cancer types suggest a role for P2X7 during tumorigenesis (See section: The function and expression of P2X7 across cancer types below). Following the demonstration of the growth-promoting activity of P2X7 *in vitro*, it was also shown in several studies that P2X7 can influence *in vivo* tumor growth and that consequently, down-modulation of the receptor by silencing or pharmacological intervention can reduce tumor burden in preclinical models ([@B97]). Adinolfi and colleagues first demonstrated the growth-promoting activity of P2X7 in four different tumor models in mice including HEK-293 cells and ACN neuroblastoma derived xenografts and syngeneic colon carcinoma and melanoma models ([@B7]). Several studies have confirmed these data and extended them, demonstrating that P2X7 blockade leads to a general reduction of tumor burden in neuroblastoma ([@B20]; [@B346]), mesothelioma ([@B21]), melanoma ([@B168]; [@B9]), glioma ([@B186]), osteosarcoma ([@B380]) and myeloid leukemia ([@B86]).

Autophagy {#s5_3}
---------

Autophagy is an important mechanism that maintains cell homeostasis by eliminating damaged cellular components and recycling them *via* metabolic pathways. By doing so, autophagy safeguards energy production under cellular stress such as starvation ([@B359]). Depending on the time of activation, autophagy can either help to prevent cancer or exert a tumor-promoting action ([@B251]). While data supporting P2X7 involvement in autophagy and cancer progression are limited, the receptor is known to act on several pathways related to autophagy including the pathway leading to autophagosome formation ([@B258]). Indeed, P2X7 was shown to activate autophagosome-lysosome fusion by upregulating Beclin1 ([@B334]; [@B231]) and LC3-II ([@B374]; [@B112]; [@B231]). In dystrophic myoblasts, P2X7-dependent activation of autophagy correlated with the ability to form the macropore but not calcium influx-induced signaling ([@B374]). The first demonstrations of P2X7-mediated trophic activity were obtained by growing cells under serum starvation where autophagy is typically induced ([@B38]; [@B4]). Cancer cells cultured under these conditions were found to upregulate P2X7 expression suggesting that autophagy can drive P2X7 overexpression and consequent trophic activity ([@B139]).

Chemotherapy-induced autophagy can be central in the modulation of the anticancer immune response ([@B192]). In particular, autophagy is a key driver in immunogenic cell death (ICD), a form of cancer cell death, which can elicit a potent immune response mediated by dendritic cells (DCs) and CD8^+^ T lymphocytes that can eradicate residual tumor cells and prevents metastasis formation following a first therapeutic intervention ([@B123]). Several classes of chemotherapeutics such as anthracyclines and oxaliplatin, are known to cause the induction of ICD ([@B123]). Before ICD takes place, premortem autophagy is required for the release of ATP in the TME where ATP attracts antigen-presenting cells *via* P2Y2 receptors ([@B236]; [@B225]) and down-regulates Treg infiltration ([@B279]), to favor an antitumor immune response. Although a clear correlation between P2X7 activation and ICD in the TME is not available, it was recently demonstrated that P2X7 expression modulates ATP levels in the TME affecting CD73 and CD39 ectonucleotidase and reducing Treg levels and fitness ([@B86]). P2X7 systemic blockade activated an ICD--like mechanism in cancer cells leading to tumor growth reduction and activation of antitumor responses while reducing the tumor-promoting inflammatory cytokine IL-1β ([@B86]).

Role of P2X7 in the Immune Response {#s5_4}
-----------------------------------

Analysis of data from P2X7 small molecule inhibitors and genetic knock out of *P2RX7* has demonstrated the key role played by P2X7 in inflammation and immunity ([@B96]; [@B11]; [@B12]) and, as a consequence, in chronic inflammatory diseases such as Duchenne muscular dystrophy ([@B116]; [@B316]), rheumatoid arthritis ([@B330]) and inflammatory bowel disease ([@B25]; [@B110]). In the TME, the permanent release of DAMPs including ATP, high mobility group box 1 (HMGB1) and calreticulin (CRT) drives chronic inflammatory settings that are supplemented by immunosuppressive signals leading to a dampening of immune effector cell responses ([@B123]). By responding to ATP proinflammatory signals, P2X7 counterbalances the potent immunosuppressive signaling driven by the ATP degradation product, adenosine ([@B217]). In the following section, we describe the role of P2X7 in inflammation and immunity and use this as a foundation to define the role of P2X7 in the TME.

ATP, released through pannexin-1 hemichannels leads to activation of P2X7 as well as other P2 receptors including P2X1, P2X4, P2X5 and P2Y6 and is associated with the activation of T-cells ([@B354]; [@B259]; [@B306]; [@B345]; [@B366]). However, the role of P2X7 in response to extracellular ATP appears to be central to the proinflammatory response including the stimulation of CD4^+^ and CD8^+^ effector T cells ([@B26]; [@B306]), stimulation of natural killer T cells ([@B42]), inhibition of differentiation in type 1 regulatory cells, promotion of Treg cell death ([@B26]; [@B307]; [@B121]) and the differentiation of inflammatory Th17 lymphocytes ([@B27]; [@B261]). P2X7 was also found to collaborate with P2Y2 to promote the chemotaxis of myeloid cells including macrophages, neutrophils and the recruitment and activation of DCs ([@B179]; [@B270]; [@B305]). P2X7 activation also promotes the immunosuppressive role of myeloid-derived suppressor cells (MDSCs) infiltrated in the TME by stimulating the release of reactive oxygen species (ROS), arginase 1 (ARG1) and transforming growth factor-β1 (TGF-β1) ([@B47]).

At the molecular level, P2X7 plays a central role in the assembly and maturation of the NLRP3 inflammasome leading to the activation of caspase 1 followed by the cleavage of pro-interleukin 1 beta (pro-IL-1β) into mature IL-1β before IL-1β is released by macrophages and other immune cells ([@B118]). Direct interaction of P2X7 with the components of the inflammasome including the apoptosis-associated speck-like protein containing a caspase recruitment domain (ASC) and the NOD-like receptor family (NLR) has been shown in neurons, astrocytes and microglial cells ([@B315]; [@B243]; [@B122]). However, following opening of the P2X7 ion channel in response to the binding of ATP, it is the depletion of cytoplasmic K^+^ that is the main driver leading to inflammasome activation ([@B304]; [@B252]). While other channels also mediate K^+^ efflux in response to ATP ([@B90]), P2X7 activated K^+^ efflux together with Ca^2+^ influx remain central to inflammasome activation and the secretion of cytokines and chemokines. Among these, IL-1β is a key proinflammatory cytokine secreted in response to P2X7 activation of the inflammasome ([@B274]; [@B275]; [@B327]). Other cytokines and chemokines are also secreted by a variety of cell types. These include IL-6 ([@B324]; [@B207]; [@B313]), IL-8 ([@B356]), IL-18 ([@B275]), tumor necrosis factor alpha (TNFα) ([@B119]; [@B313]), CC-chemokine ligand 2 (CCL2 also named MCP-1) ([@B262]; [@B207]; [@B313]), CCL3 ([@B197]), CCL7 ([@B207]), CXCL2 ([@B314]; [@B207]), and prostaglandin E2 (PGE2) ([@B263]; [@B32]). P2X7 also triggers activation and shedding of matrix metalloproteases (MMPs) from peripheral-blood mononuclear cells (PBMCs) ([@B147]; [@B145]; [@B375]). It also has been suggested that P2X7 plays a role in the resolution of inflammation through secretion of the anti-inflammatory cytokines IL-10 and TGFβ and proteins such as annexin A1 ([@B70]; [@B47]; [@B245]; [@B87]). However, other reports have demonstrated P2X7 mediated inhibition of soluble HLA-G and IL-10 secretion by monocytes ([@B291]) and the negative modulation of HLA-G in women affected with herpes virus 6 A ([@B269]).

P2X7 may cooperate in mediating the response to pathogen-associated molecular patterns (PAMPs) such as lipopolysaccharides (LPS) through a potential LPS binding motif in the P2X7 C-terminal tail ([@B88]). LPS activation of TLR receptor also stimulates the production of pro-IL-1β, which is then processed by caspase-1 following P2X7 and NLRP3 inflammasome activation ([@B352]). Similarly, TLR2 and 4 were found to cooperate with P2X4 and P2X7 when activated by biglycan, a ubiquitous leucine-rich repeat proteoglycan found in the extracellular matrix ([@B28]). P2X7 was shown to interact with the myeloid differentiation primary response 88 (MyD88) to activate the NF-kB signaling pathway ([@B220]). MyD88 mediates NF-kB signaling downstream of the TLR receptors and might mediate the cooperation between P2X7 and TLR signaling pathways. P2X7 together with CD14 as a coreceptor was found to support LPS binding and the internalization of P2X7 ([@B81]). Overall, these studies support a model whereby activation of TLR2 and 4 cooperate with P2X7 to drive chronic inflammatory settings. While ATP, PAMPs and biglycan were found to be key ligands of P2X7 and TLR receptors, in the TME, DAMPs such as ATP and HMGB1, a ligand for TLR4, are also present in significant concentrations and capable of driving the chronic inflammatory settings described above ([@B123]).

Role of the P2X7 in Immunometabolism {#s5_5}
------------------------------------

Metabolic reprogramming and the maintenance of mitochondrial fitness are increasingly recognized as key factors in T lymphocyte differentiation and effector functions ([@B53]; [@B30]). Generation of long-lived T memory cells depends on efficient oxidative phosphorylation and fatty acid oxidation, while effector T cells are mainly dependent on glycolysis ([@B268]). Therefore, mitochondria have a central role in directing T cell functions. The receptors and pathways mediating the regulation of mitochondrial metabolism modulation in T cells are still poorly characterized, however it is increasingly clear that the P2X7 receptor plays an important role. P2X7 has long been known as a prototypic cytotoxic receptor ([@B93]), but its tonic activity also supports healthy mitochondrial metabolism, enhances ATP production *via* the respiratory chain and promotes cell growth ([@B4]; [@B5]). The specific role of P2X7 in supporting metabolic fitness of long-lived T memory cells has now been demonstrated ([@B53]). Stimulation of the P2X7 receptor *via* extracellular ATP is crucial to promote memory CD8^+^ T cell generation and long-term survival that is mediated mainly by a trophic effect on mitochondrial metabolism and the related increase in ATP synthesis. These data support a previous report from Di Virgilio and coworkers showing that P2X7 receptor expression has a broad effect on immunometabolism through modulation of glycolysis ([@B19]). Indeed, aerobic glycolysis is also impaired in P2X7-deficient CD8^+^ T lymphocytes ([@B53]). Thus, the P2X7 receptor may function as a "metabolic sensor" that links the DAMP extracellular ATP, to the intracellular energy-producing machinery (i.e., oxidative phosphorylation and glycolysis).

The "metabolic sensor" function of the P2X7 receptor is of particular relevance at inflammatory and tumor sites since the extracellular ATP concentration in the inflammatory or tumor microenvironments (IME and TME, respectively) is several-fold higher than in the healthy interstitium ([@B272]; [@B97]). The impact of such a high extracellular ATP concentration on the viability of tumor infiltrated lymphocytes due to opening of the macropore is not known. While it is possible that loss of viability may take place, the long-term presence of infiltrated lymphocytes suggests that modulation of abrogation of macropore function through one or more of the mechanisms described in [**Table 1**](#T1){ref-type="table"} is likely to take place in these cells. Although details of the mechanism whereby P2X7 'transduces' the information carried by high extracellular ATP is not fully known, key immune functions are significantly affected by P2X7 activation ([@B96]; [@B91]). Most importantly, P2X7 is a major stimulus for Il-1β and IL-18 release, and therefore for the initiation of inflammation, potentiation of antigen presentation by DCs and an efficient immune response, including antitumor immune responses ([@B253]; [@B97]). Converging reports by multiple laboratories have confirmed the initial observation by Di Virgilio and coworkers of a potent P2X7-mediated growth-promoting and stimulatory effect on human T lymphocytes ([@B37]; [@B306]; [@B372]; [@B376]; [@B82]). P2X7 is upregulated in Treg and T follicular helper cells (Tfh) that are severely inhibited by its activation ([@B127]; [@B344]; [@B163]). This is hypothesized to have important implications for host-microbiota interaction in gut-associated secondary lymphoid organs where ATP released by bacteria down-modulates the activity of resident Tfh cells, thus reducing secretion of high affinity IgA and their binding to commensal bacteria ([@B99]). Grassi and coworkers have shown that P2X7 deletion affects microbiota composition and, in consequence, host metabolic homeostasis ([@B276]; [@B282]). This might be significant in view of the known role of microbiota in the pathogenesis of several types of cancer and the influence of microbiota on the response to immune checkpoint inhibitors ([@B141]; [@B384]; [@B351]).

P2X7 and Purinergic Signaling in Antitumor Immunity {#s5_6}
---------------------------------------------------

The function of the P2X7 receptor in the TME is better understood in the context of the overall mechanisms that control the extracellular ATP concentration ([@B12]). Of importance is the role of CD39 and CD73 ectonucleotidases, that hydrolyze ATP to adenosine ([@B349]). Adenosine has long been considered one of the main drivers of immunosuppression ([@B24]). Yet, recent data demonstrates that the P2X7, CD39, and CD73 axis also plays a significant role in the modulation of the TME immune component. P2X7 activation can be promoted by targeting CD39, with beneficial effects on antitumor responses that cannot be explained merely by the inhibition of adenosine generation ([@B217]). The use of P2X7 targeted small molecule inhibitors and *P2RX7* genetic knock out in a murine melanoma model leads to modulation of CD39 and CD73 expression levels on several immune cell populations including Tregs, CD4^+^ effector lymphocytes, macrophage and DCs ([@B86]). P2X7 null mice show a decrease in tumor-infiltrated CD8^+^ T cells and an increase in Tregs overexpressing the fitness markers PD-1, OX40, and CD73. This outcome correlated with a decrease of extracellular ATP levels. In contrast, systemic inhibition of P2X7 with the antagonist A740003 did not affect the number of tumor-infiltrated CD8^+^ and Treg lymphocytes but increased the number of CD4^+^ effector T cells. A reduced expression of CD39 and CD73 was also observed on CD4^+^ T cells and in DCs highlighting the importance of the crosstalk between P2X7, CD39, and CD73 in these cell types ([@B86]). The collaboration between P2X7 and CD39 was further demonstrated in two recent studies investigating the antitumoral activity of a CD39 blocking antibody ([@B217]; [@B369]). Blocking of CD39 led to reduced tumor burden and metastatic spread in several murine models. Anti-CD39 antitumoral activity required the activation of P2X7 on immune cells as P2X7-mediated activation of the NLRP3 inflammasome led to IL-18 release by myeloid cells and induction of pyroptosis ([@B217]; [@B369]). These data demonstrate that P2X7 collaboration with CD39 plays a central role in the regulation of anti-tumor immunity.

Membrane Blebbing {#s5_7}
-----------------

Membrane blebbing consists of plasma membrane sections protruding and retracting to create protrusions at the cell surface. Although the mechanism leading to membrane blebbing is not fully understood, P2X7 is one of the proteins that have been shown to initiate this mechanism upon sustained ATP stimulation for several minutes ([@B226]). ATP mediated opening of the P2X7 macropore leads to a large Ca^2+^ influx that can induce membrane blebbing. Multiple proteins are involved in this mechanism. These include the serine/threonine kinase ROCK I ([@B250]), heat shock protein HSP90 that negatively regulates receptor-mediated blebbing ([@B3]) and the epithelial membrane protein 2 (EMP-2) ([@B365]). EMP-2 was shown to interact with the P2X7 C-terminal tail suggesting that P2X7 mediated blebbing requires opening of the macropore ([@B365]). While membrane blebbing is commonly associated with cellular stress and the initiation of the apoptotic pathway, P2X7 may also be involved in triggering reversible membrane blebbing allowing leukocytes to migrate and invade through extracellular matrices ([@B285]). Finally, P2X7-mediated membrane blebbing has been proposed as an early step leading to shedding of microvesicles in the microenvironment ([@B285]).

Release of Microvesicles {#s5_8}
------------------------

Since the discovery that P2X7 is central to the release of the proinflammatory cytokine IL-1β by macrophages, there have been extensive investigations on how this mechanism occurs, since IL-1β belongs to the leaderless secretory protein group lacking the secretory signal necessary for conventional protein secretion through the endoplasmic reticulum route ([@B102]). These studies have shown that IL-1β secretion is instead mainly caused by P2X7 induced nonconventional pathways including microvesicle shedding, exosomes and modified lysosomes ([@B226]; [@B120]; [@B281]; [@B286]; [@B222]; [@B278]). Other studies further showed involvement of P2X7 in microvesicles that release cytokines by fibroblasts and microglia ([@B324]; [@B48]), HIV particles by macrophages ([@B142]) and tissue factor by macrophages and DCs ([@B39]; [@B247]).

Release of ROS {#s5_9}
--------------

During environmental stress such as ionizing radiation, UV, or heat exposure, increased ROS production mediates oxidative stress, damages cellular structures and initiates cell death. However, low levels of ROS can act as signaling molecules. In phagocytes, ROS are used as bactericides to complete the phagocytosis process ([@B80]; [@B289]). Hence, cells need to control ROS levels tightly in order to meet their physiological needs, while preventing cell death ([@B108]). Production of ROS is mediated mainly by NADPH oxidases (NOXs), and the electron transport chain in mitochondria. During tumor development, oncogenic stimulation, increased metabolic activity and mitochondrial defects lead to increased ROS production forcing cancer cells to increase their antioxidant capacity to prevent cell death ([@B289]). Several reports have shown the induction of ROS production downstream of P2X7 activation \[reviewed in ([@B158])\]. They show that P2X7-mediated Ca^2+^ influx leads to activation of kinases that phosphorylate NADPH oxidases (NOXs) to activate the production of ROS ([@B248]; [@B353]). However, there are contradictory reports on the nature of the pathway involved in the phosphorylation of NOXs. In microglial cells, p38 MAPK and PI3K but not ERK1/2 have been shown to mediate ROS production ([@B267]). In macrophages, two studies have shown activation of ERK1/2 downstream of PKC, c-Src, Pyk2 but no involvement of PI3K or p38 MAPK ([@B211]; [@B230]) while Noguchi et al. reported activation of the ASK1, p38 MAPK signaling pathway is required for ROS production ([@B255]). Low levels of ATP stimulation increase mitochondrial Ca^2+^ content leading to hyperpolarization of mitochondrial potential and increased ATP production ([@B4]). In line with these data, P2X7 was shown to drive the expression of glycolytic enzymes leading to increased glycolysis and oxidative phosphorylation that sustains cancer cell growth in the absence of glucose and serum ([@B19]).

Control of P2X7 Localization as a Mean to Modulate P2X7 Function {#s6}
================================================================

P2X7 has been shown to localize in several cellular compartments including the plasma membrane, endoplasmic reticulum (ER), lysosomes, and phagosomes ([@B204]; [@B293]). In human monocytes and lymphocytes, P2X7 was found to be localized mainly intracellularly while differentiation of monocytes into macrophages led to P2X7 localizing to the plasma membrane ([@B170]; [@B148]; [@B157]). In contrast, in mouse microglia and macrophages, P2X7 localizes mainly at the plasma membrane ([@B55]). In cancer cells, Gilbert and colleagues showed that nfP2X7 colocalizes with the ER marker, calreticulin indicating that a misfolded form of the receptor may be retained intracellularly. This was further supported by the relocalization of this form to the plasma membrane upon treatment with small molecule corrector KM11060 that increases the rate of protein secretion ([@B137]). Interestingly, this increased membrane expression was also stimulated by high ATP concentrations (500 µM and above) that suggests that cells may be using ER to plasma membrane localization as a mean to regulate P2X7 functions ([@B137]).

Palmitoylation of cysteine residues at the hinge of the C-terminal tail was shown to be required for P2X7 to localize to the plasma membrane and associate with lipid rafts ([@B140]). While several reports have confirmed P2X7 interaction with lipid rafts in multiple cell types ([@B31]; [@B124]; [@B40]), the localization of P2X7 in lipid rafts may not be exclusive. Garcia-Marcos et al. have identified two P2X7 pools located in both lipid raft and nonlipid raft membrane compartments ([@B124]). They further showed that the nonlipid raft P2X7 pool can open a nonselective cation channel while the lipid raft P2X7 pool only is able to activate phospholipase A2 (PLA~2~) ([@B124]). Hence, the nature of the lipid content in the membrane surrounding P2X7 receptors can regulate receptor signaling and ultimately its function. Indeed, cholesterol was shown to inhibit P2X7 macropore function ([@B294]; [@B194]) while sphingomyelin and 1-palmitoyl-2-oleoyl-sn-glycero-3-phospho-(1'-rac-glycerol) (POPG) were shown to enhance macropore function ([@B194]). Similarly, phosphatidylinositol 4,5-bisphosphate (PIP2) was shown to modulate P2X7 ion channel function ([@B382]). Although no direct interaction was found between P2X7 and PIP2, several residues in the C-terminal tail (R385, K387 and K395) were shown to be involved in PIP2 regulation. The I568N polymorphism also located in the P2X7 C-terminal tail was shown to impair P2X7 trafficking to the membrane ([@B362]) while the H155Y polymorphism increased P2X7 localization to the plasma membrane ([@B57]).

Evidence from several groups points to the existence of signaling cassettes located in the C-terminal tail of P2X7 which supports P2X7 trafficking to the plasma membrane ([@B89]; [@B362]; [@B323]; [@B67]). Indeed, Lenertz have shown the presence of an ER retention/retrieval cassette in the P2X7 C-terminal tail near R576 ([@B211]). This cassette allows P2X7 monomers to be retained in the ER while being assembled into trimers. P2X7 channels are then addressed to the plasma membrane through the secretory pathway ([@B211]). A similar mechanism has already been reported for other multimeric membrane receptors such as the N-methyl-D-aspartate (NMDA), glutamate receptor and the γ-aminobutyric acid type B (GABAB) receptor ([@B241]). The section of P2X7 C-terminal tail overlapping with that cassette also was found to bind to phospholipids as well as LPS in a macrophage cell line thereby modulating receptor membrane localization and its capacity to signal through the MAP Kinase and NF-κB pathway ([@B88]; [@B220]).

The Function and Expression of P2X7 Across Cancer Types {#s6_1}
-------------------------------------------------------

The presence of P2X7 has been shown in a large number of studies using tumor-derived biopsies, cell lines, xenografts and syngenic murine models across multiple and diverse cancer types. The majority of these publications, which demonstrate the presence of P2X7, have not directly assessed functionality of the P2X7 macropore. Given the high concentration of ATP in solid tumors, present at levels capable of inducing P2X7 pore activation ([@B272]) and thereby death, it is unlikely that cells expressing fully functional P2X7 could survive in the TME over extended time periods. Therefore, it is probable that cells expressing P2X7 within the TME need to express P2X7 predominantly in a form where pore activity is attenuated. Despite this attenuation of pore function, it is clear from a number of studies that the P2X7 expressed in these cancer cells retains significant signaling functionality and the ability to drive the formation, survival and metastatic potential of tumor cells as previously reported ([@B184]; [@B7]; [@B20]; [@B86]; [@B137]).

The P2X7 receptor is expressed on a number of cancer types including, but not limited to prostate, lung, kidney, colorectal, gastric, breast, cutaneous squamous-cell and basal-cell carcinomas, melanoma, leukemia, neuroblastoma, glioma, ovarian, cervical, bladder, papillary thyroid, pancreatic and bone cancer. This includes nfP2X7 ([@B35]; [@B137]). The key data demonstrating the expression and function of P2X7 on these cancer types is discussed below while [**Table 2**](#T2){ref-type="table"} provides a list of references per cancer type.

### Prostate Cancer {#s6_1_1}

In an immunohistochemistry (IHC) study looking at 116 prostate cancer biopsies using an affinity-purified polyclonal antibody to the E200 epitope of P2X7 (supplied by Biosceptre), P2X7, in a nonpore functioning form, was identified in all malignant samples regardless of their stage or the age of the patient ([@B319]). This was confirmed using a mouse monoclonal antibody (BPM09, supplied by Biosceptre) ([@B228]). In another study, increased expression of nfP2X7 was observed as prostate disease progressed ([@B36]). P2X7 expression by IHC also was compared with the levels of prostate-specific antigen (PSA) in 174 prostate cancer biopsies ([@B321]). Increased nfP2X7 staining correlated with increased PSA levels indicating that P2X7 may provide a diagnostic biomarker candidate for early prostate cancer. These results were consistent with those of a separate study demonstrating increased P2X7 mRNA and protein expression in prostate tumor samples compared with normal tissue ([@B288]). Increased P2X7 expression correlates with expression of epidermal growth factor receptor (EGFR) and estrogen receptor (ER)α, which are well known drivers of cancer cell proliferation, suggesting that P2X7 might cooperate with these receptors to promote cell proliferation ([@B288]). These observations support the proposed role for P2X7 in cancer cell survival and proliferation ([@B5]; [@B6]). Indeed, functional P2X7 was shown to drive invasion and metastasis of prostate cancer cell lines stimulated by extracellular ATP ([@B130]; [@B284]).

### Lung Cancer {#s6_1_2}

In a study analyzing P2X7 mRNA expression in 26 patients with nonsmall cell lung cancer (NSCLC), compared with 21 patients with chronic obstructive pulmonary disease (COPD) without signs of malignancy, higher P2X7 expression was observed in bronchoalveolar lavage derived cells of tumors with distant metastases ([@B308]). P2X7 is also expressed in human NSCLC cell lines including A549, PC9 and H292 cells but not in the nonmalignant bronchial epithelial cells BEAS-2B ([@B34]; [@B340]; [@B185]; [@B341]). In H292 cells, inhibition or down-regulation of P2X7 abrogated TGF-β1 induced migration and actin remodeling. P2X7 is required for TGF-β1-induced exocytosis of ATP that then acts as a paracrine factor in lung cancer cell model. Overall, these data suggest a role for P2X7 in promoting invasion and the development of aggressive forms of lung cancer.

### Kidney Cancer {#s6_1_3}

Clear-cell renal cell carcinoma (ccRCC) is the most common form of renal cell carcinoma. In a study analyzing 273 ccRCC patients by IHC, P2X7 expression was correlated with the clinicopathologic features and cancer-specific survival (CSS) ([@B221]). Although intratumoral P2X7 expression was lower than peritumoral P2X7 expression, those patients with high intratumoral P2X7 expression had a worse prognosis. Overall, these data suggest that intratumoral P2X7 is involved in the progression of ccRCC. In contrast, the significant P2X7 expression found in peritumoral tissues may reflect P2X7 involvement in the TME. Further exploration of the cell type expressing P2X7 in ccRCC TME is now needed to better understand the nature of that involvement.

### Colorectal and Gastric Cancer {#s6_1_4}

P2X7 protein was identified by IHC with staining distributed throughout the cell in a small number of normal colorectal epithelia and colon adenocarcinomas ([@B215]). Qian et al. demonstrated that high P2X7 expression correlated with tumor size, lymph nodes metastasis, TNM stage and was also associated with poor overall survival in a cohort of 116 colon carcinoma ([@B283]). These contradicting results suggest that there may be subtypes of colorectal cancer characterized by their level of P2X7 expression. Indeed, Zhang et al. analyzed normal tissue and colorectal cancer samples from 97 patients and found both P2X7 high and P2X7 low populations with P2X7 high population having increased metastasis and reduced survival ([@B381]). Both P2X7 and nfP2X7 were identified in human colorectal cancer epithelium although the nfP2X7 expression was much more significant ([@B35]; [@B137]). While nfP2X7 was identified in the human HT-29 and Colo-205 colon cancer cell lines ([@B34]), other reports have shown P2X7 expression in human HCT8, Caco-2, Colo-205, and murine MCA38 colon cancer cell lines and the latter cell line was found to possess functional P2X7 macropore ([@B79]; [@B206]; [@B46]). Analysis of P2X7 expression in 156 gastric cancers corelated P2X7 expression with tumor burden and poor survival suggesting that P2X7 may be involved in the progression of gastric cancer ([@B64]).

### Breast Cancer {#s6_1_5}

An IHC study analyzing nfP2X7 expression in 40 breast tumors of diverse histological subtypes demonstrated that nfP2X7 expression was absent in normal and hyperplastic breast epithelial samples while *in situ* or invasive lobular or ductal carcinoma expressed high levels of nfP2X7 ([@B320]). Tumor cells from invasive carcinomas showed membrane staining as opposed to intracellular staining in *in situ* carcinomas. Therefore, nfP2X7 membrane staining may be stage-specific and nfP2X7 expression levels may help to distinguish between different stages of breast cancer. P2X7 mRNA and protein also were upregulated under hypoxic conditions in the noninvasive breast cancer cell line MCF-7 which has a nonfunctional P2X7 pore ([@B338]; [@B66]). In contrast, two independent studies looking at P2X7 expression showed a reduction of P2X7 staining in breast cancer versus normal tissue ([@B215]; [@B175]). The antibodies used in these studies were raised against the C-terminal tail of the receptor and are therefore likely to mainly detect P2X7 variant A. These antibodies are unable to discriminate between functional P2X7 and nfP2X7. Hence, while discrepancies exist for the expression of P2X7 variant A in breast cancer, nfP2X7 appears to be specifically upregulated at the surface of breast cancer cells. Tan et al. reported higher P2X7 expression levels in the breast cancer tissues when compared with normal breast tissue ([@B343]). Furthermore, a positive correlation was observed between P2X7 expression and the estrogen receptor (ER)+ by qRT-PCR, western blot and immunohistochemistry analysis.

### Cutaneous Squamous-Cell and Basal-Cell Carcinomas {#s6_1_6}

P2X7 is highly expressed both in nodular basal cell carcinomas (BCC) and in infiltrative BCC cells where it was shown to be present in some tumor cell nuclei ([@B143]). P2X7 expression was also found in the human squamous cell carcinoma (SCC) cell line A431, ([@B143]). nfP2X7 protein also was upregulated in 25 SCC compared to 20 keratoacanthomas (KA) ([@B317]). Using an affinity purified sheep polyclonal antibody to nfP2X7, systemic treatment of advanced cat SCC showed decreased lesion size ([@B36]). In a more recent study, the presence of nfP2X7 was shown in BCC and antibodies specific for nfP2X7 rather than fully functional P2X7 were shown to be a safe treatment for BCC with 65% of patients showing reduced lesion area, 20% showing stable tumor size and 15% with increased lesion area ([@B136]). Overall, these data support the targeting of nfP2X7 in BCC and SCC.

### Melanoma {#s6_1_7}

In an IHC study looking at 80 human melanoma biopsies, nfP2X7 protein was overexpressed in malignant tissues when compared with nonmalignant samples. P2X7 upregulation was also observed on keratinocytes of the epidermis surrounding the tumor ([@B318]). A study analyzing P2X7 in 14 human melanoma biopsies confirmed the upregulation of P2X7 in melanoma with over 75% of samples staining positively ([@B358]). Upregulation of P2X7 in melanoma samples was confirmed in cell lines at the mRNA level. Indeed, whole genome microarray screening of the NCI-60 cancer cell line panel has shown full length P2X7 upregulation as a hallmark of melanoma cell lines ([@B311]; [@B290]; [@B296]). The human melanoma cell line A375 was found to express P2X7 variant A and to have a functional large pore ([@B358]).

### Leukemia {#s6_1_8}

P2X7 is upregulated in T-cell acute lymphoblastic leukemia and in murine erythroleukemia (MEL) cells ([@B76]; [@B69]). In MEL cells, P2X7 was also shown to have a functional macropore ([@B76]). P2X7 was also upregulated in pediatric leukemias ([@B72]) as well as in human myeloid leukaemic cell lines F-36P and HL-60 ([@B373]). In a separate study, P2X7 mRNA and protein were upregulated in 8 out of 11 cell lines, 69 out of 87 bone marrow mononuclear cell (BMMC) samples from leukemia patients and 9 out of 10 myelodysplastic syndrome (MDS) patients ([@B379]). Furthermore, P2X7 also was significantly upregulated in acute myelogenous leukemia (AML) and acute lymphoblastic leukemia (ALL) ([@B379]). P2X7 expression was found to be higher in AML subtypes having poor prognosis. Following standard induction, P2X7 was upregulated in a group with a low remission rate ([@B379]). Increased P2X7 expression was found in lymphocytes from patients with the evolutive form of B-cell chronic lymphocytic leukemia (B-CLL) ([@B2]). Furthermore, P2X7 expression correlated with the severity of B-CLL. However, the large molecular weight pore function was not assessed in this study ([@B2]). In a separate study, antibodies targeting P2X7 were shown to bind to the surface of B-CLL cells. While the analysis of P2X7 membrane expression by flow cytometry suggests that the B-CLL populations tested are not fully uniform, data suggest that B-CLL populations with both functional and nonfunctional macropore can be identified ([@B148]). Overall, these data support a role for P2X7 in the progression of leukemia and the development of aggressive forms of the disease.

### Neuroblastoma {#s6_1_9}

In an IHC study, P2X7 was highly expressed in neuroblastoma irrespective of the tumor grade. P2X7 was also expressed in several neuroblastoma cell lines including ACN, GI-CA-N, HTLA-230, GI-ME-N, LAN-5, LAN-1, SK-N-BE-2, and SH-SY-5Y with cell surface staining characterized for at least ACN ([@B287]). P2X7 stimulation *in vitro* with ATP did not induce apoptosis of neuroblastoma cells but instead stimulated their proliferation *via* the enhanced secretion of substance P, which suggests that these cells were nonfunctional for P2X7 macropore ([@B287]). In an independent study, P2X7 mRNA expression was analyzed in 131 patients with neuroblastoma ([@B20]). High P2X7 expression correlated with poor prognosis while patients with low P2X7 expression levels had less aggressive tumors ([@B20]).

### Glioma {#s6_1_10}

Both mRNA and protein were detected in human glioma cell lines U-138MG, U-251MG, and M059J. P2X7 was shown to mediate cell death in response to ATP in glioma cells ([@B356]; [@B342]; [@B128]; [@B113]). While U-138 MG and U-251 MG cells appeared to have a nonfunctional P2X7 pore, M059J glioma cells were reported as having functional receptor macropore ([@B128]). P2X7 is also upregulated in mouse GL261 glioma cells ([@B44]). P2X7 was also upregulated in an *in vivo* model where rats received an intra-striatal injection of C6 glioma cells ([@B300]). In these cells, P2X7 promoted chemotaxis *in vitro,* which suggests that P2X7 may play a role in the metastasis process of glioma ([@B300]). In a separate study, Gehring et al. showed that high P2X7 expression was a good prognostic factor for glioma radiosensitivity and survival probability ([@B129]). P2X7 was highly upregulated at the mRNA and protein level in tumor tissue as opposed to peritumoral and adjacent normal tissue ([@B339]). P2X7 upregulation was also observed in cancer stem cells from GBM cultured under hypoxic conditions. This evidence supports the potential involvement of P2X7 in cancer stem cells ([@B339]).

### Ovarian Cancer {#s6_1_11}

P2X7 expression was analyzed by IHC in nine human ovarian carcinoma biopsies and compared with ovarian surface epithelium in healthy tissue ([@B348]). P2X7 was highly expressed in both healthy tissue and ovarian carcinoma ([@B348]). P2X7 also was found to be expressed in the human ovarian cancer cell lines SKOV-3 and CAOV-3 ([@B348]). Both P2X7 and nfP2X7 were expressed in ovarian cancer tissue ([@B35]; [@B137]).

### Cervical Cancer {#s6_1_12}

IHC analysis of squamous cell cancer of the cervix showed increased nfP2X7-specific membranous staining when compared to normal tissue ([@B35]). In contrast, Li et al. have reported a decreased expression of full length P2X7 in tissues of complex hyperplasia with atypia or endometrial adenocarcinoma compared to normal endometrium, simple hyperplasia or complex hyperplasia tissues ([@B214]).

### Bladder Cancer {#s6_1_13}

Using Protein Pathway Array (PPA) to investigate the expression of 285 proteins and phosphoproteins in bladder urothelial cell carcinoma tissues and adjacent nontumor tissues, Hu et al. reported that expression of P2X7 was an independent factor, favorable for overall survival ([@B174]). Both P2X7 and nfP2X7 were confirmed to be expressed in bladder cancer tissue in separate IHC studies ([@B35]; [@B137]).

### Papillary Thyroid Cancer {#s6_1_14}

P2X7 mRNA was upregulated in 37 human papillary thyroid cancer (PTC) samples when compared with adjacent normal tissue ([@B325]). P2X7 protein upregulation was also confirmed by IHC in all malignant tissues tested including the classical and follicular forms of the disease ([@B325]). Adjacent normal tissue was devoid of P2X7 staining. P2X7 staining was found to be diffuse in the cytoplasm and intense at the cell surface of malignant thyrocytes ([@B325]). P2X7 mRNA and protein was also detected in FB1 and FB2 human thyroid cancer cell lines. In response to ATP, these cells showed a P2X7 dependent release of IL-6, a cytokine associated with aggressiveness of PTC ([@B298]; [@B325]). P2X7 upregulation in PTC was confirmed by IHC in two independent studies ([@B215]; [@B153]). P2X7 upregulation was shown to correlate with tumor growth, capsular infiltration and lymph node metastases ([@B153]; [@B208]). Additional reports showed nfP2X7 expression in PTC tissue ([@B34]; [@B35]). Overall, these studies support a correlation between P2X7 and nfP2X7 expression and the development of aggressive PTC.

### Pancreatic Cancer {#s6_1_15}

P2X7 mRNA and protein was shown to be upregulated in chronic pancreatitis and pancreatic cancer tissue and cell lines *in vitro* and *in vivo* ([@B205]; [@B132]; [@B133]). P2X7 large pore functionality was not assessed in these studies. Other reports demonstrated both P2X7 and nfP2X7 expression in pancreatic cancer tissue ([@B35]; [@B137]).

### Bone Cancer {#s6_1_16}

P2X7 was upregulated in osteosarcoma, Ewing sarcoma, chondromyxoid fibroma as well as in bone cancer cell lines such as SaOs-2 and HOS ([@B125]; [@B18]; [@B219]). SaOs-2 cells have a functional P2X7 large pore ([@B18]). Moreover, P2X7 upregulation plays a key role in several malignancies metastasising to the bone that supports an involvement of P2X7 in the host tissue during the metastatic process (reviewed in ([@B94]; [@B8]; [@B9]). P2X7B splice variant was upregulated in osteosarcoma and its expression was associated with cell proliferation ([@B138]).

Therapeutic Approaches Taken to Target P2X7 {#s7}
===========================================

Several pharmaceutical organizations have engaged in the development of both small-molecules and biologics directed against P2X7 ([@B235]; [@B41]; [@B180]) ([**Table 3**](#T3){ref-type="table"}). These developments can be seen in the increasing number of filed patents for P2X7 targeted treatment ([@B160]; [@B322]; [@B264]; [@B277]). Early development of small molecule inhibitors targeted the P2X7 orthosteric site to compete ATP mediated P2X7 activation. However, the lack of specificity of these inhibitors led to the identification and development of several classes of inhibitors that bind to the inter-subunit allosteric pocket preventing ATP induced rotation of each subunit and closure of the turret ([@B193]). Within this inter-subunit allosteric pocket, several point mutants including but not limited to F88A, D92A, F95A, and F103A were identified to play an important role in the mode of action of these inhibitors ([@B16]; [@B17]; [@B51]). Engagement of this allosteric pocket allowed progressive development of antagonists in the low nanomolar range ([**Table 2**](#T2){ref-type="table"}) while providing better selectivity for P2X7 against other P2X family members ([@B103]; [@B16]; [@B17]; [@B51]). Initial identification of lead candidates against the inter-subunit allosteric pocket revealed compounds with good activity against human P2X7 but inactive against the rat isoform making pharmacology studies difficult ([@B239]; [@B240]; [@B65]). However, docking of these candidates in the inter-subunit allosteric pocket highlighted the importance of human F95 (L95 in rat P2X7) in developing pi-stacking interactions with inhibitors ([@B65]; [@B16]; [@B17]).

###### 

Small molecule inhibitors and biologics used against P2X7.

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Molecule                                                                        Format                                  pEC50/pIC50 (method used)                                                                                           Binding site/other targets                                                                                                                                                                                                                              Development stage                                                                                                                                                                                               Disease settings                                                                     References
  ------------------------------------------------------------------------------- --------------------------------------- ------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------ -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  **Nonselective inhibitors**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              

  Suramin                                                                         Small molecule                          \> 300 μM (change in current)                                                                                       Orthosteric site; Binds to multiple other targets including several P2 receptor subtypes, several growth factors, human immunodeficiency virus (HIV) reverse transcriptase, vasoactive intestinal peptide receptors and G protein--coupled receptors.   In the clinic                                                                                                                                                                                                   Used as antiparasitic agent against trypanosomes infection.\                         ([@B242]; [@B336]; [@B181])
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      Tested in the clinic for the treatment of autism and hand foot and mouth disease.\   
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      Tested as combination with chemotherapy in multiple solid and blood born tumors.     

  NF279 (Suramin analog)                                                          Small molecule                          20 µM (Ca^2+^ influx at 3min)\                                                                                      Orthosteric site\                                                                                                                                                                                                                                       Preclinical                                                                                                                                                                                                     N/A                                                                                  ([@B103])
                                                                                                                          891 nM (Yo-Pro uptake)                                                                                              High affinity to P2X~1~                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      

  MRS2159                                                                         Small molecule                          1.7 µM (Ca^2+^ influx at 3min)\                                                                                     High affinity to P2X~1~                                                                                                                                                                                                                                 Preclinical                                                                                                                                                                                                     N/A                                                                                  ([@B103])
                                                                                                                          288 nM (Yo-Pro uptake)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           

  2\_,3\_-dialdehyde ATP (oxidized ATP)                                           Small molecule closely related to ATP   100--300 μM (change in current)                                                                                     Orthosteric site                                                                                                                                                                                                                                        Preclinical                                                                                                                                                                                                     N/A                                                                                  ([@B336]; [@B238]; [@B169])

  pyridoxalphosphate-6-azophenyl-2',4'-disulfonic acid (PPADS)                    Small molecule                          3.2 µM (Ca^2+^ influx at 3min)\                                                                                     Orthosteric site                                                                                                                                                                                                                                        Preclinical                                                                                                                                                                                                     N/A                                                                                  ([@B103]; [@B178])
                                                                                                                          1.2 µM (Yo-Pro uptake)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           

  pyridoxal-5′-phosphate-6-(2′-naphthylazo-6′-nitro-4′,8′-disulphonate) (PPNDS)   Small molecule                          407 nM (Ca^2+^ influx at 3min)\                                                                                     Orthosteric site                                                                                                                                                                                                                                        Preclinical                                                                                                                                                                                                     N/A                                                                                  ([@B103])
                                                                                                                          200 nM (Yo-Pro uptake)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           

  KN-62                                                                           Small molecule                          10 µM (Ca^2+^ influx at 3min)\                                                                                      Inter-subunit allosteric pocket and central cavity involving D92, F103, T90, and V312 in human P2X7.\                                                                                                                                                   Preclinical                                                                                                                                                                                                     N/A                                                                                  ([@B103]; [@B51])
                                                                                                                          214 nM (Yo-Pro uptake)                                                                                              High concentrations (≥1 μM) also block Ca2^+^/calmodulin-dependent protein kinase II.                                                                                                                                                                                                                                                                                                                                                                                                                                                                        

  Brilliant Blue G (BBG)                                                          Small molecule                          \< 100 µM (Ca^2+^ influx at 3min)\                                                                                  Inter-subunit allosteric pocket and central cavity involving D92, F103, and V312 residues.\                                                                                                                                                             Preclinical                                                                                                                                                                                                     N/A                                                                                  ([@B103]; [@B51])
                                                                                                                          1.9 µM (Yo-Pro uptake)                                                                                              Also blocks voltage-gated sodium channels.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   

  **Selective inhibitors**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 

  A438079                                                                         Small molecule                          123 nM (Ca^2+^ influx at 3min)\                                                                                     Inter-subunit allosteric pocket involving F88, D92, T94, F95, and F103 residues.                                                                                                                                                                        Preclinical                                                                                                                                                                                                     N/A                                                                                  ([@B254]; [@B103]; [@B17])
                                                                                                                          933 nM (Yo-Pro uptake)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           

  A740003                                                                         Small molecule                          44 nM (Ca^2+^ influx at 3min)\                                                                                      Inter-subunit allosteric pocket involving F88, D92, T94, F95 and F103, M105 and V312 residues.                                                                                                                                                          Preclinical                                                                                                                                                                                                     N/A                                                                                  ([@B171]; [@B103]; [@B193]; [@B17])
                                                                                                                          93 nM (Yo-Pro uptake)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            

  A804598                                                                         Small molecule                          11 nM (Ca^2+^ influx)                                                                                               Inter-subunit allosteric pocket involving F88, F95, F103, M105, and F108 residues.                                                                                                                                                                      Preclinical                                                                                                                                                                                                     N/A                                                                                  ([@B104]; [@B193])

  A839977                                                                         Small molecule                          20--150 nM (Ca^2+^ influx and Yo-Pro uptake)                                                                        Not known                                                                                                                                                                                                                                               Preclinical                                                                                                                                                                                                     N/A                                                                                  ([@B172])

  AZ10606120                                                                      Small molecule                          10 - 200 nM (Ethudium uptake and Ca^2+^ influx)                                                                     Inter-subunit allosteric pocket involving residues 73 to 79, T90, T94, F103, and V312 residues.                                                                                                                                                         Preclinical                                                                                                                                                                                                     N/A                                                                                  ([@B237]; [@B193]; [@B16])

  AZ11645373                                                                      Small molecule                          10--20 nM (change in current and Yo-Pro uptake)                                                                     Inter-subunit allosteric pocket involving L83, S86, F88, D92, T94, F95, P96, F108, I310, and V312 residues.                                                                                                                                             Preclinical                                                                                                                                                                                                     N/A                                                                                  ([@B331]; [@B65]; [@B51])

  AZD9056                                                                         Small molecule                          12 nM (IL-1β secretion)                                                                                             Not known                                                                                                                                                                                                                                               Evaluated in a Phase 2b against rheumatoid arthritis. Clinical trial number: NCT00520572                                                                                                                        Rheumatoid arthritis                                                                 ([@B199]; [@B233])

  GSK1482160                                                                      Small molecule                          Kd=5.09 ± 0.98 nmol/l, Ki=2.63 ± 0.6 nmol/l (\[11C\]GSK1482160 binding to HEK293-hP2X7 live cells)                  noncompetitive, negative allosteric modulators                                                                                                                                                                                                          Phase 1: First Time in Human Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and the Effect of Food of Single Assending Doses of GSK1482160. Clinical trial number: NCT00849134   Pain from inflammatory disease such as arthritis                                     ([@B96]; [@B164])

  GW791343                                                                        Small molecule (positive modulator)     Negative allosteric modulator of human P2X7 but positive allosteric modulator of rat P2X7 at high concentrations.   Inter-subunit allosteric pocket involving F103 and V312 residues.                                                                                                                                                                                       Preclinical                                                                                                                                                                                                     N/A                                                                                  ([@B239]; [@B193])

  CE-224535 (Pfizer)                                                              Small molecule                          4 nM (Yo-Pro uptake)\                                                                                               noncompetitive, negative allosteric modulators                                                                                                                                                                                                          Phase 2a: Efficacy and safety of CE-224,535, an antagonist of P2X7 receptor, in treatment of patients with rheumatoid arthritis inadequately controlled by methotrexate.\                                       Rheumatoid arthritis                                                                 ([@B107]; [@B96])
                                                                                                                          1 nM (IL-1β secretion)                                                                                                                                                                                                                                                                                                                                                      Clinical trial number: NCT00628095;                                                                                                                                                                                                                                                                  

  EVT-401 (Evotec)                                                                Small molecule                          Not known                                                                                                           Not known                                                                                                                                                                                                                                               Phase 1 in healthy volunteers to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of EVT-401.                                                                                        Inflammatory conditions such as Rheumatoid Arthritis                                 M.G. Kelly, J. Kincaid, Bicycloheteroaryl compounds as P2X7 modulators and uses thereof, US 7297700, 2007.\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           Evotec Announces the Successful Completion of the First Phase 1 Study with EVT 401:\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           [https://www.evotec.com/en/invest/news--announcements/press-releases/p/evotec-announces-the-successful-completion-of-the-first-phase-i-study-with-evt-401-an-oral-p2x7-receptor-antagonist---very-good-safety-profile-and-confirmed-on-target-activity-4447](https://www.evotec.com/en/invest/news–announcements/press-releases/p/evotec-announces-the-successful-completion-of-the-first-phase-i-study-with-evt-401-an-oral-p2x7-receptor-antagonist—very-good-safety-profile-and-confirmed-on-target-activity-4447)

  JNJ47965567                                                                     Small molecule                          5 nM (Ca^2+^ influx)                                                                                                Inter-subunit allosteric pocket involving F88, F103, M105, F108 and V312 residues.                                                                                                                                                                      Preclinical                                                                                                                                                                                                     N/A                                                                                  ([@B45]; [@B193])

  JNJ42253432                                                                     Small molecule                          20nM (Ca^2+^ influx)                                                                                                Not known                                                                                                                                                                                                                                               Preclinical                                                                                                                                                                                                     N/A                                                                                  ([@B223])

  JNJ54232334                                                                     Small molecule                          0.3 nM against human P2X7, 32 nM against rat P2X7 (Ca^2+^ influx)                                                   Not known                                                                                                                                                                                                                                               Preclinical                                                                                                                                                                                                     N/A                                                                                  ([@B224])

  JNJ54140515                                                                     Small molecule                          79 nM against rat P2X7 (Ca^2+^ influx)                                                                              Not known                                                                                                                                                                                                                                               Preclinical                                                                                                                                                                                                     N/A                                                                                  ([@B224])

  JNJ54166060                                                                     Small molecule                          4 nM (Ca^2+^ influx)                                                                                                Not known\                                                                                                                                                                                                                                              Preclinical                                                                                                                                                                                                     N/A                                                                                  ([@B337])
                                                                                                                                                                                                                                              Inhibits CYP3A (IC50 = 2 μM)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 

  **Biologics**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            

  L4                                                                              mAb                                     5nM (change in current)                                                                                             Not known                                                                                                                                                                                                                                               Preclinical                                                                                                                                                                                                     N/A                                                                                  ([@B60])

  Hano43                                                                          Rat mAb                                 N/A                                                                                                                 Not known                                                                                                                                                                                                                                               N/A                                                                                                                                                                                                             N/A                                                                                  ([@B13])

  Hano44                                                                          Rat mAb                                 N/A                                                                                                                 Paratope includes R151 in finger-like structure cysteine-rich region                                                                                                                                                                                    N/A                                                                                                                                                                                                             N/A                                                                                  ([@B13])

  K1G                                                                             Rabbit polyclonal Ab.                   N/A                                                                                                                 Paratope includes R151 in finger-like structure cysteine-rich region                                                                                                                                                                                    N/A                                                                                                                                                                                                             N/A                                                                                  ([@B13])

  1F11                                                                            Rat mAb                                 N/A                                                                                                                 Not known                                                                                                                                                                                                                                               N/A                                                                                                                                                                                                             N/A                                                                                  ([@B207])

  13A7 nanobody                                                                   Bivalent nanobody-Fc                    0.5 nM (inhibit CD62L shedding in mouse cell line)                                                                  Bind finger-like structure cysteine-rich region (same region as Hano44) mouse P2X7. No binding to human P2X7                                                                                                                                            N/A                                                                                                                                                                                                             N/A                                                                                  ([@B82])

  14D5 nanobody (enhancer)                                                        Bivalent nanobody-Fc                    0.1 nM (enhanced CD62L shedding in mouse cell line)                                                                 Bind finger-like structure cysteine-rich region (same region as Hano44) mouse P2X7. No binding to human P2X7                                                                                                                                            N/A                                                                                                                                                                                                             N/A                                                                                  ([@B82])

  Dano1-Fc                                                                        Bivalent nanobody-Fc                    0.2 nM (Ca^2+^ influx and DAPI uptake)                                                                              Not known                                                                                                                                                                                                                                               Preclinical                                                                                                                                                                                                     N/A                                                                                  ([@B82])

  BIL010t                                                                         Polyclonal Anti-nfP2X7 ointment         N/A                                                                                                                 E200 peptide in P2X7 extracellular domain                                                                                                                                                                                                               Investigation of the Safety and Tolerability of BSCT (Anti-nf-P2X7) 10% Ointment (Completed, has results)\                                                                                                      Basal Cell carcinoma (BCC)                                                           ([@B136])
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      Clinical trial number: NCT02587819                                                                                                                                                                                                                                                                   

  BIL06v                                                                          Vaccine                                 N/A                                                                                                                 E200 peptide in P2X7 extracellular domain                                                                                                                                                                                                               A Phase 1 Study to Evaluate the Safety, Tolerability, Immunogenicity and Antitumor Activity of BIL06v/Alhydrogel in Patients with Advanced Solid Tumors. (Active, not recruiting)\                              Solid Tumors                                                                         
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      Clinical trial number: ACTRN12618000838213                                                                                                                                                                                                                                                           
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Several of these small molecules including AZD9056 (AstraZeneca), CE-224,535 (Pfizer), EVT-401 (Evotec), and GSK1482160 (GlaxoSmithKline plc) have entered clinical studies to treat rheumatoid arthritis as well as other inflammatory conditions ([**Table 2**](#T2){ref-type="table"}). Although all clinical data are not yet available, no clear benefits to patients have been observed so far ([@B180]; [@B96]). A recent report of an anti-P2X7 bivalent nanobody-Fc with IC~50~in the sub-nanomolar range developed by Ablynx (now Sanofi) appear to show promising preclinical efficacy in chronic inflammatory disease models ([@B82]). As reports increasingly highlight the critical role of P2X7 and ATP in tumor biology and its microenvironment, the rationale for targeting P2X7 in cancer in single or combination therapies is becoming increasingly relevant ([@B96]; [@B217]). Indeed, the recent report of the well-tolerated BIL010t, topical anti-P2X7 treatment of BCC (Biosceptre) revealed promising patient outcomes with 65% of patients treated showing reduced lesion area and 20% with stable disease ([@B136]). Assessment of safety and immunogenicity of an anti P2X7 vaccine (BIL06v -- Biosceptre) used in patients with advanced solid tumors is ongoing in Australia.

Conclusion {#s8}
==========

Since the discovery of P2X7 as a cytotoxic receptor, studies have shown that the role of P2X7 in tumor biology and its microenvironment is much more complex than initially thought. Because of the significant involvement of P2X7 in the diverse mechanisms that drive tumor progression, this receptor is now believed to be of significant value as a target for the development of new cancer therapies. Preclinical and clinical evidence of P2X7-targeted therapeutics demonstrate the potential for these candidates as innovative cancer therapies. Furthermore, the interplay between the activities of P2X7 in tumor cell biology and antitumor immune responses indicates that P2X7 targeted therapies could also be of significant value when used in combination therapies. Therefore, additional studies, to better link the molecular mechanisms associated with P2X7 activation, signaling and cancer development, are now needed to drive highly innovative, safe and effective first in class therapeutics into the clinic.
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